RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB. (12th June 2019)

• Record Type: Journal Article
• Authors: Smith, S.D.; Munoz, J.; Stevens, D.A.; Smith, S.M.; Feldman, T.A.; Ye, J.C.; de Vos, S.; Hess, B.T.; Miller, C.B.; Khatcheressian, J.L.; Birrell, M.R.; Leeds, J.M.; Coffey, G.P.; Conley, P.B.; Michelson, G.C.; Curnutte, J.T.; Hamlin, P.A.
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 61
• Page End: 62
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.30_2629
• Languages: English
• ISSNs: 0278-0232